Literature DB >> 8630581

Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.

M J Belman1, W C Botnick, J W Shin.   

Abstract

Dynamic hyperinflation (DH) is a major pathophysiologic consequence of airflow limitation during exercise in patients with chronic obstructive pulmonary disease (COPD) and an important contributing factor to breathlessness. In this study we aimed to examine the effect of inhaled beta agonist therapy on DH during exercise in these patients and the relationship between changes in DH and breathlessness. In 13 COPD patients (mean age 65.1 +/- 2.0, FEV1 1.20 +/- 0.17, FEV1/FVC 40 +/- 3) we measured pulmonary function tests, exercise breathlessness by Borg score, and exercise flow volume and pressure volume loops on two separate days. Prior to testing, patients randomly received inhaled placebo or albuterol on the first test day and the alternative medication on the second test day. From measurements of exercise inspiratory capacity (IC), we calculated the end-expiratory and end-inspiratory lung volumes (EELV, EILV). We used esophageal pressure recordings to measure peak inspiratory esophageal pressure (Pesins) during exercise and this was related to the maximal capacity for pressure generation taking into account lung volume and airflow changes (Pcapi). Bronchodilator caused significant increase in both FEV1 and FVC (+0.23 and +0.51, p<0.01). Comparisons of breathlessness, exercise volumes, and pressures were made at the highest equivalent work load. There was a significant reduction in the peak exercise EELV/TLC (80 +/- 0.02% to 76 +/- 0.02%, p<0.05) while the peak EILV/TLC decreased by 2% (97 +/- 1% to 95 +/- 1%, p<0.05). The peak Pesins/Pcapi decreased (0.79 +/- 0.10 to 0.57 +/- 0.05, p<0.05), and the Pcapi - Pesins increased (7.4 +/- 3 to 13.0 +/- 3 cm H2O, p<0.05). There was significant improvement in neuroventilatory coupling for volume change (Pesins/Pcapi/VT/TLC 5.45 +/- 0.5 to 3.25 +/- 1.0, p<0.05). There was a significant reduction in breathlessness as measured by Borg score (4.5 +/- 0.7 to 3.1 +/- 0.5, p<0.05) and there was a significant correlation between delta Borg and delta EILV/TLC (r=0.771, p<0.01) with a trend for Pesins/Pcapi/VT/TLC (r=0.544, p=0.067). There was also a significant correlation between delta EELV/TLC and delta Pesins/Pcapi/VT/TLC (r=0.772, p<0.01). The relationships between delta Borg, delta resting volumes, and flow rates were not significant. We conclude that in patients with COPD, inhaled bronchodilator reduces exercise DH and improves inspiratory pressure reserve and neuroventilatory coupling. Changes in DH and neuroventilatory coupling were the main determinants of reduced breathlessness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630581     DOI: 10.1164/ajrccm.153.3.8630581

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

Review 1.  Health status measurement in chronic obstructive pulmonary disease.

Authors:  P W Jones
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease.

Authors:  I Vogiatzis; O Georgiadou; S Golemati; A Aliverti; E Kosmas; E Kastanakis; N Geladas; A Koutsoukou; S Nanas; S Zakynthinos; C Roussos
Journal:  Thorax       Date:  2005-06-17       Impact factor: 9.139

3.  Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study.

Authors:  Yun Li; Yin-Huan Li; Shuo Li; Yu-Wen Luo; Rui Xiao; Yu-Xia Huang; Jin-Lun Huang; Yi-Tai Chen; Rong-Chang Zhi; Xin Chen
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Usefulness of inspiratory capacity measurement in COPD patients in the primary care setting.

Authors:  Antonio Madueño; Antonio Martín; Juan-Antonio Péculo; Esther Antón; Alejandra Paravisini; Antonio León
Journal:  Int J Gen Med       Date:  2009-12-29

Review 5.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

6.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Authors:  V Brusasco; R Hodder; M Miravitlles; L Korducki; L Towse; S Kesten
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 7.  Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation.

Authors:  J R Hurst; J A Wedzicha
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

Review 8.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

Review 9.  Pharmacological treatment of chronic obstructive pulmonary disease.

Authors:  Paolo Montuschi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.